mRNA新冠疫苗与带状疱疹报告关联研究
该研究利用全球药物警戒数据库VigiBase,采用病例/非病例不成比例分析,比较mRNA新冠疫苗与流感疫苗接种后带状疱疹的报告风险。
要点
- mRNA新冠疫苗接种后带状疱疹报告风险显著高于流感疫苗(报告比值比1.9)。
- 40岁以下人群带状疱疹报告风险低于40岁及以上人群(报告比值比0.39)。
- 带状疱疹反应多为轻度和不常见,尤其见于40岁以上接种者。
核心结论
- mRNA新冠疫苗接种后可能出现轻度且不常见的带状疱疹反应,报告频率高于流感疫苗接种,尤其在40岁以上人群中。
研究设计与样本
- 基于全球药物警戒数据库VigiBase的不成比例分析(病例/非病例统计方法),截至2021年6月30日。
主要发现
- 与流感疫苗相比,mRNA新冠疫苗带状疱疹报告比值比为1.9(95%CI 1.8-2.1)。
- 40岁以下人群带状疱疹报告风险低于年长者,报告比值比0.39(95%CI 0.36-0.41)。
关键数值与推荐
- 带状疱疹报告风险比较:mRNA新冠疫苗 vs 流感疫苗,报告比值比1.9(95%CI 1.8-2.1)。
- 年龄分层比较:40岁以下 vs 年长者的报告比值比0.39(95%CI 0.36-0.41)。
临床怎么用
- 临床药师应知晓mRNA新冠疫苗接种后带状疱疹报告风险升高,尤其关注40岁以上接种者。
- 对接种后出现带状疱疹样症状者,可结合用药史进行不良反应评估与报告。
局限性
- 基于药物警戒数据库的不成比例分析,不能确立因果关系。
- 研究结果需进一步分析确认该风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several cases of herpes zoster (HZ) following mRNA COVID-19 vaccination (BNT162b2 and mRNA-1273) have been reported, and the first epidemiological evidence suggests an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID-19 vaccination. We performed disproportionality analyses (case/non-case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID-19 vaccine recipients compared to influenza vaccine recipients and according to patient age. To 30 June 2021, of 716 928 reports with mRNA COVID-19 vaccines, we found 7728 HZ cases. When compared to influenza vaccines, mRNA COVID-19 vaccines were associated with a significantly higher reporting of HZ (reporting odds ratio 1.9, 95% CI 1.8-2.1). Furthermore, we found a reduced risk of reporting HZ among under 40-year-old persons compared to older persons (reporting odds ratio 0.39, 95% CI 0.36-0.41). Mild and infrequent HZ reactions may occur shortly after mRNA COVID-19 vaccination, at higher frequency than reported with influenza vaccination, especially in patients over 40 years old. Further analyses are needed to confirm this risk.
引用
- Préta LH, Contejean A, Salvo F, et al. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273). Br J Clin Pharmacol. 2022. PMID: 35174524. doi:10.1111/bcp.15280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。